Nordicus Partners Corporation's subsidiary, Orocidin A/S, is advancing its lead candidate, Orocidin (QR-01), towards clinical trials for periodontitis. The company announced that the toxicity program for Orocidin (QR-01) is scheduled to commence in January 2025, with completion expected by the third quarter of the same year. This milestone will enable the initiation of a pilot efficacy study in patients before the end of 2025.
Orocidin (QR-01) represents a novel approach to treating periodontitis by targeting three critical aspects of the disease. The therapy aims to reduce inflammation, eradicate bacterial infections, and promote bone regeneration, addressing the multifaceted nature of periodontitis. Patent applications have been filed to protect the innovative design of Orocidin (QR-01).
Addressing Unmet Needs in Periodontitis Treatment
Periodontitis, a severe form of gum disease, affects a significant portion of the adult population worldwide. Current treatments often involve antibiotics and surgical interventions, which may have limitations in long-term efficacy and patient compliance. Orocidin (QR-01) offers a potential alternative by simultaneously targeting the key pathological features of the disease.
"We are very pleased that Orocidin has reached this critical stage of development, bringing us closer to demonstrating the efficacy of our solution and addressing a significant unmet need in dental health," said Allan Wehnert, Founder and CEO of Orocidin. He added that Orocidin reflects Nordicus’ dedication to developing innovative solutions that can improve lives and create value for stakeholders.
Nordicus Partners' Strategic Focus
Nordicus Partners Corporation is a U.S. publicly traded business accelerator and holding company focused on supporting Nordic life sciences companies. The company's acquisition of Orocidin A/S in 2024 underscores its commitment to advancing innovative therapies in areas of unmet medical need. Nordicus also acquired Bio-Convert ApS, which is focused on oral leukoplakia, in 2024.
With the initiation of the toxicity program, Orocidin (QR-01) is poised to take a significant step towards clinical development, potentially offering a new treatment option for patients suffering from periodontitis.
